Share Name Share Symbol Market Type Share ISIN Share Description
Faron Pharma LSE:FARN London Ordinary Share FI4000153309 ORD NPV (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 692.50p 675.00p 710.00p 700.00p 692.50p 692.50p 0 14:00:06
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1.0 -7.9 -33.2 - 193.31

Faron Pharma Share Discussion Threads

Showing 1 to 24 of 25 messages
Chat Pages: 1
DateSubjectAuthorDiscuss
10/5/2017
12:24
Good to see this on the move back towards 800p today
jamesd888
09/5/2017
08:42
See this moving too new highs
jamesd888
08/5/2017
14:08
probably close around 700p today
jamesd888
08/5/2017
14:08
Today's RNS were good news and share price drops might be a good opp to buy now.
jamesd888
08/5/2017
13:41
The independent data monitoring committee has now reviewed the trial data four times picture of drugs in trial Up to 300 ARDS patients will take part in the trial Faron Pharmaceuticals Ltd's (LON: FARN) has received another recommendation that its ongoing INTEREST trial for lead drug Traumakine can continue as planned with no changes. The independent data monitoring committee has now reviewed the trial data four times with the next scheduled review at 240 recruited patients and likely to be in the third quarter of 2017. INTEREST is a Phase III double-blind, randomised, parallel-group comparison of the efficacy and safety of Traumakine in patients suffering with moderate to severe ARDS, an often fatal orphan disease with a mortality rate of approximately 30-45%. CLICK HERE: For a daily round-up of all the Proactive news The study, designed to include up to 300 patients, is currently being conducted in 60 hospital intensive care units (ICU) in Belgium, Finland, France, Germany, Italy, Spain and UK. The INTEREST trial protocol is targeting a 50% reduction in all cause mortality at day 28 between placebo and treatment arm (from 30% to 15%). Dr Markku Jalkanen, Faron’s chief executive said: "We were again very delighted to learn that the IDMC gave us another recommendation to continue the INTEREST study as planned. “We are looking forward to their next recommendation in Q3 2017, which we hope to confirm our plans for the future of the product and for ARDS patients." There is no treatment for ARDS currently, which is often linked to pneumonia and characterised by widespread capillary leakage and inflammation in the lungs.
jamesd888
10/4/2017
12:19
Ooo do we think this is the top for now?
rizler
06/4/2017
20:58
My gut feeling is big things to come Keep watching BOO because its cheaper but good JOG is another with good prospects All the best
saturn5
05/4/2017
01:40
Saturn5 - Wondered what you were on about LOL! Then I looked at my post again and realized my iphone or "brain" must have been playing tricks on me when I typed the message as it was rather misleading. I have corrected it. So unfortunately I am not in but have been watching FARN go up and up :-( Well done for managing to get in lower than it is now.
lauders
04/4/2017
19:08
I thin ph3 will go ok This is proving to be one of my best shares BOO is also doing well. I will report on my 0ther winners later this week
saturn5
04/4/2017
12:27
I too am overwhelmed by the way this has risen in such a short space of time. Truth is though that they have a great drug candidate to satisfy a large unmet need so should see rapid commercialisation assuming the Ph3 goes to plan.I see no point in selling yet. Could easily see £10 this year.
longshanks
02/4/2017
10:34
Lauders You were very lucky Could be very good this year
saturn5
15/3/2017
09:37
Most are probably amazed at the rise and too stunned comment! Wish I had purchased at 250p just a short time ago!
lauders
15/3/2017
09:11
Vacuum of sellers, my best guess. Did anyone attempt to figure out what might traumakine be worth upon a positive P3 outcome?
dacian
14/3/2017
17:46
Not much comment here... considering the rocket.
capt bligh
14/3/2017
17:45
Not much comment here... considering the rocket.
capt bligh
02/3/2017
12:44
Hi Lauders, don't think the chart has much relevance at this stage but nevertheless, it does look pretty at the top of the thread. What made me invest in Faron, (apart from Apad :-) )were the traumakine potential and the ceo. Dr Jalkanen seems the sort of honest, capable and shareholder friendly kind of guy, my gut feeling tells me. But first the bear case: very simple, if traumakine fails to get MA (marketing authorisation) then a 50% share price dive ( my best guess) will promptly happen within the first 5 min of the trading day. I have no doubt about that. The bull case is a bit more complicated, but the more I read about it the more I think the conversation now is how well will this product sell. In my view, the MA is in the bag , main reason being the bar was lowered to 50% and in Phase 2 they achieved 80% ( reduction in mortality rates). Many drugs make it through the P3 stages but simply don't sell, or if there is a genuine blockbuster out there ( blue sky, billion with a B! sales potential ) it gets gobbled up by the big boys after Phase 2, generally. If traumakine achieves anywhere near the 80% reduction in mortality rates as per P2 trials then I can't see how a doctor can justify not using a drug like that where 30-40% of the ards patients die. Only if the drug is effective and makes a meaningful difference, then it will be a financial success as well. I think there is a realistic , good chance of that happening with traumakine. Not a blockbuster, but a realistic chance of success. How successful ?!... it depends how good the drug will prove to be.
dacian
02/3/2017
08:50
Many thanks capt bligh! Much better. Pretty impressive chart at the moment!
lauders
01/3/2017
15:18
Any chance of some charts here capt bligh? Please :-) Interested in following FARN too.
lauders
28/2/2017
08:41
interesting rns
capt bligh
09/2/2017
20:38
Today's update reads much better face to face: Http://www.stocktube.com/video/6892/faron-pharmaceuticals-to-build-on-success-of-extremely-exciting-2016-6892.html
dacian
03/2/2017
21:09
Thanks for starting the thread. Been a keen follower over the last two months.
longshanks
31/1/2017
20:06
The attraction here is that THEY HAVE THE PATENT
saturn5
28/1/2017
14:45
Thanks for opening the fan club capt bligh, I couldn't resist the privilege of writing the first post. There's the best summary that I could find on Faron: Http://cordis.europa.eu/result/rcn/184021_en.html and their product traumakine Http://www.traumakine.eu/
dacian
27/1/2017
11:39
Saw a presentation last night ...was impressed and bought... anyone else?
capt bligh
Chat Pages: 1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:35 V: D:20170820 19:18:19